Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,810 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management system of home transfusion in Japan: A nationwide survey in 2019.
Tanaka A, Fujita H, Ohashi K, Tsujikawa A, Uchiyama K, Ito T, Kawashima K, Kodama R, Mine T, Okuda M, Endoh T, Fukuyoshi Y, Kitazawa J, Sueoka E, Nagai K, Ishida A, Matsuzaki K, Kato Y, Takanashi K, Takahashi K. Tanaka A, et al. Among authors: nagai k. Vox Sang. 2023 Jan;118(1):59-67. doi: 10.1111/vox.13380. Epub 2022 Dec 1. Vox Sang. 2023. PMID: 36454538
Home transfusions are implemented using diverse approaches in Japan.
Tanaka A, Fujita H, Ohashi K, Tsujikawa A, Uchiyama K, Ito T, Kawashima K, Kodama R, Mine T, Okuda M, Endoh T, Fukuyoshi Y, Kitazawa J, Sueoka E, Nagai K, Ishida A, Matsuzaki K, Kato Y, Takanashi K, Takahashi K. Tanaka A, et al. Among authors: nagai k. Vox Sang. 2023 Nov;118(11):938-946. doi: 10.1111/vox.13518. Epub 2023 Sep 6. Vox Sang. 2023. PMID: 37671662
Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study Group.
Chiwata M, Itonaga H, Sato S, Hashimoto M, Fujioka M, Kasai S, Sakamoto H, Toriyama E, Nakashima J, Kamijo R, Kitanosono H, Kobayashi Y, Horai M, Taguchi M, Matsuo M, Makiyama J, Takasaki Y, Matsuo E, Horio K, Ando K, Sawayama Y, Taguchi J, Kawaguchi Y, Tsushima H, Imanishi D, Imaizumi Y, Yoshida S, Jo T, Nonaka H, Moriuchi Y, Nagai K, Yokota KI, Hata T, Miyazaki Y. Chiwata M, et al. Among authors: nagai k. Intern Med. 2021 Jul 15;60(14):2207-2216. doi: 10.2169/internalmedicine.6620-20. Epub 2021 Feb 22. Intern Med. 2021. PMID: 33612681 Free PMC article.
Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group.
Sakai M, Miyazaki Y, Matsuo E, Moriuchi Y, Hata T, Fukushima T, Imaizumi Y, Imanishi D, Taguchi J, Iwanaga M, Tsushima H, Inoue Y, Takasaki Y, Tsuchiya T, Komoda M, Ando K, Horio K, Moriwaki Y, Tominaga S, Itonaga H, Nagai K, Tsukasaki K, Tsutsumi C, Sawayama Y, Yamasaki R, Ogawa D, Kawaguchi Y, Ikeda S, Yoshida S, Onimaru Y, Tawara M, Atogami S, Koida S, Joh T, Yamamura M, Matsuo Y, Soda H, Nonaka H, Jinnai I, Kuriyama K, Tomonaga M. Sakai M, et al. Among authors: nagai k. Int J Hematol. 2009 Apr;89(3):319-325. doi: 10.1007/s12185-009-0263-z. Epub 2009 Mar 6. Int J Hematol. 2009. PMID: 19266256
Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group.
Itonaga H, Tsushima H, Imanishi D, Hata T, Doi Y, Mori S, Sasaki D, Hasegawa H, Matsuo E, Nakashima J, Kato T, Horai M, Taguchi M, Matsuo M, Taniguchi H, Makiyama J, Sato S, Horio K, Ando K, Moriwaki Y, Sawayama Y, Ogawa D, Yamasaki R, Takasaki Y, Imaizumi Y, Taguchi J, Kawaguchi Y, Yoshida S, Joh T, Moriuchi Y, Nonaka H, Soda H, Fukushima T, Nagai K, Kamihira S, Tomonaga M, Yanagihara K, Miyazaki Y. Itonaga H, et al. Among authors: nagai k. Leuk Res. 2014 Jan;38(1):76-83. doi: 10.1016/j.leukres.2013.10.022. Epub 2013 Nov 5. Leuk Res. 2014. PMID: 24262285 Free article.
RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL.
Itonaga H, Kato T, Sawayama Y, Katsuoka S, Furumoto T, Matsumoto N, Sasaki D, Yamada Y, Hashimoto M, Fujioka M, Sakamoto H, Hasegawa H, Imaizumi Y, Nagai K, Yanagihara K, Miyazaki Y. Itonaga H, et al. Among authors: nagai k. Leuk Lymphoma. 2024 Feb;65(2):275-278. doi: 10.1080/10428194.2023.2276058. Epub 2024 Jan 24. Leuk Lymphoma. 2024. PMID: 37909304 No abstract available.
Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan.
Matsuo E, Miyazaki Y, Tsutsumi C, Inoue Y, Yamasaki R, Hata T, Fukushima T, Tsushima H, Imanishi D, Imaizumi Y, Iwanaga M, Sakai M, Ando K, Sawayama Y, Ogawa D, Kawaguchi Y, Nagai K, Tsukasaki K, Ikeda S, Moriuchi Y, Yoshida S, Honda M, Taguchi J, Onimaru Y, Tsuchiya T, Tawara M, Atogami S, Yamamura M, Soda H, Yoshida Y, Matsuo Y, Nonaka H, Joh T, Takasaki Y, Kawasaki C, Momita S, Jinnai I, Kuriyama K, Tomonaga M. Matsuo E, et al. Among authors: nagai k. Int J Hematol. 2007 Feb;85(2):132-9. doi: 10.1532/IJH97.06157. Int J Hematol. 2007. PMID: 17321991 Clinical Trial.
3,810 results